Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial
Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study.
Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice.
Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis.
“Veterinary Medicines” page
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β.
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
Estrogen and testosterone therapies in multiple sclerosis.
Cuprizone neurotoxicity in the rat: morphologic observations.
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
GlaxoSmithKline Product Development Pipeline
Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication.
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study.
A validated gene regulatory network and GWAS identifies early regulators of T cell-associated diseases.
Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
The force awakens: insights into the origin and formation of microglia.
A study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis (TENERE)
Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination.
Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment.
Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone.
Mechanism of action of mitoxantrone.
Myelin Oligodendrocyte Glycoprotein-Associated Pediatric Central Nervous System Demyelination: Clinical Course, Neuroimaging Findings, and Response to Therapy.
Pages
« first
‹ previous
…
22
23
24
25
26
27
28
29
30
…
next ›
last »